Phase I trial of MEDI-507 in CD2-positive lymphoproliferative disease.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Siplizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; Lymphoid leukaemia; Lymphoproliferative disorders; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors MedImmune
- 25 Mar 2012 Actual patient number (29) added as reported by ClinicalTrials.gov. (NCT00071825)
- 25 Mar 2012 Actual patient number (29) added as reported by ClinicalTrials.gov. (NCT00071825)
- 25 Mar 2012 Actual patient number (29) added as reported by ClinicalTrials.gov. (NCT00071825)